Caris Life Sciences (CAI) EBITDA Margin (2024 - 2026)

Caris Life Sciences' EBITDA Margin history runs 3 years deep, the most recent figure standing at 2.44% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 5037.0% year-over-year to 2.44%; the TTM figure through Mar 2026 stood at 11.94% (up 6119.0% YoY), while the FY2025 annual figure was 5.56%, up 6792.0% from the prior year.
• EBITDA Margin for Q1 2026 stood at 2.44%, down from 30.19% in the prior quarter.
• The five-year high for EBITDA Margin was 30.19% in Q4 2025, with the low at 66.98% in Q2 2024.
• The 3-year median for EBITDA Margin is 19.22% (2024), against an average of 20.69%.
• The sharpest annual moves came in 2025 and 2026: EBITDA Margin jumped 7493 bps in 2025, then surged 5037 bps in 2026.
• Caris Life Sciences' EBITDA Margin stood at 28.52% in 2024, then surged by 206 bps to 30.19% in 2025, then plunged by 92 bps to 2.44% in 2026.
• Business Quant data shows CAI's EBITDA Margin at 2.44% in Q1 2026, 30.19% in Q4 2025, and 15.05% in Q3 2025.